Applicability of a Modified Rat Model of Acute Arthritis for Long-Term Testing of Drug Delivery Systems

Applicability of a Modified Rat Model of Acute Arthritis for Long-Term Testing of Drug Delivery Systems

Blog Article

Episodes of inflammation and pain are predominant features of arthritic joint diseases.Drug delivery systems (DDS) could reduce Nail Polish inflammation and pain long-term without chances of infection upon multiple injections.To allow for long-term evaluation of DDS, we modified a previously published acute arthritis model by extending follow-up periods between flare-ups.

Unilateral synovial inflammation of the knee was induced by intra-articular injection of streptococcal cell wall peptidoglycan polysaccharide (PGPS), and flare-ups were induced by intravenous PGPS injections every 4 weeks for a total duration of 84 days.In PGPS-reactivated animals, joint swelling, pain behavior, post mortem synovitis, and osteophyte formation were notable features.Hepatitis, splenitis and inflammation of non-primed joints were observed as ARNICA CREAM systemic side effects.

To test the applicability of the modified arthritis model for long-term testing of DDS, the duration of anti-inflammatory and analgesic effects of a corticosteroid released from two different polymer-based platforms was evaluated.The current modified arthritis model has good applicability for testing of DDS for a prolonged period of time.Furthermore, the novel autoregulatory polyesteramide (PEA) microsphere platform releasing triamcinolone acetonide (TAA) was benchmarked against poly lactic-co-glycolic acid (PLGA) and reduced joint swelling and pain behavior more potently compared to TAA-loaded PLGA microspheres.